Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | CTSG | P08311 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8932920 | 0.88 | LIPG (0.42) | CTSBCA12CA9ELANECTSG | |
| SCHEMBL11889488 | 0.85 | CTSB (0.42) | CTSBCA12CA9METAP2PSIP1 | |
| SCHEMBL1714372 | 0.85 | LIPG (0.51) | ELANECTSGRECQLPPARGPPARA | |
| SCHEMBL330706 | 0.85 | CTSB (0.53) | CTSBPSIP1HSD11B1LOXL2 | |
| SCHEMBL10181520 | 0.83 | PSIP1 (0.45) | CTSBCA12CA9METAP2PSIP1 | |
| SCHEMBL10181521 | 0.83 | DRD2 (0.42) | CTSBCA12CA9METAP2PSIP1 | |
| SCHEMBL150860 | 0.82 | MYC (0.46) | CTSBCA12CA9METAP2HSD11B1 | |
| SCHEMBL4446851 | 0.82 | CTSB (0.40) | CTSBCA12CA9METAP2PSIP1 | |
| SCHEMBL31319091 | 0.82 | MYC (0.46) | CTSBCA12CA9METAP2HSD11B1 | |
| SCHEMBL301797 | 0.82 | CA2 (0.47) | CTSBCA12CA9METAP2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111694215-B | Photoresist composition and method for forming photolithographic pattern | 常州强力先端电子材料有限公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-111694215-A | Photoresist composition and method for forming photolithographic pattern | 常州强力先端电子材料有限公司 | 2020-09-22 | — | — | CN | disclosed |
| US-20180258038-A1 | N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-09-13 | — | — | US | disclosed |
| US-10000450-B2 | N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| US-20170166524-A1 | N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-06-15 | — | — | US | disclosed |
| US-9611214-B2 | N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-04-04 | — | — | US | disclosed |
| CN-103613527-B | N, N-substituted 3-aminopyrrolidine compounds useful as monoamine reuptake inhibitors | OTSUKA PHARMACEUTICAL CO.,LTD. (JP) | 2016-02-24 | — | — | CN | disclosed |
| US-20140288065-A1 | N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-09-25 | — | — | US | disclosed |
| US-8815871-B2 | N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-08-26 | — | — | US | disclosed |
| CN-103613587-A | N, N-substituted 3-aminopyrrolidine compounds useful as monoamine reuptake inhibitors | OTSUKA PHARMA CO LTD | 2014-03-05 | — | — | CN | disclosed |
| EP-1818722-A1 | CHEMICAL AMPLIFICATION PHOTORESIST COMPOSITION, PHOTORESIST LAYER LAMINATE, METHOD FOR PRODUCING PHOTORESIST COMPOSITION, METHOD FOR PRODUCING PHOTORESIST PATTERN AND METHOD FOR PRODUCING CONNECTING TERMINAL | TOKYO OHKA KOGYO CO., LTD. (JP) | 2007-08-15 | — | — | EP | disclosed |
| CN-1938261-A | Preparation method for aminophenol compound | OTSUKA PHARMA CO LTD (JP) | 2007-03-28 | — | — | CN | disclosed |
| EP-1761823-A1 | METHOD OF FORMING PLATED PRODUCT USING NEGATIVE PHOTORESIST COMPOSITION AND PHOTOSENSITIVE COMPOSITION USED THEREIN | TOKYO OHKA KOGYO CO., LTD. (JP) | 2007-03-14 | — | — | EP | disclosed |
| EP-1727782-A1 | METHOD OF PRODUCING AMINOPHENOL COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-12-06 | — | — | EP | disclosed |
| WO-2006121218-A1 | N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006003757-A1 | METHOD OF FORMING PLATED PRODUCT USING NEGATIVE PHOTORESIST COMPOSITION AND PHOTOSENSITIVE COMPOSITION USED THEREIN | TOKYO OHKA KOGYO CO., LTD. (JP) | 2006-01-12 | — | — | WO | disclosed |
| WO-2005092832-A1 | METHOD OF PRODUCING AMINOPHENOL COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-10-06 | — | — | WO | disclosed |
| US-6838229-B2 | Chemically amplified negative photoresist composition for the formation of thick films, photoresist base material and method of forming bumps using the same | TOKYO OHKA KOGYO CO., LTD. (JP) | 2005-01-04 | — | — | US | disclosed |
| US-20030039921-A1 | Chemically amplified negative photoresist composition for the formation of thick films, photoresist base material and method of forming bumps using the same | TOKYO OHKA KOGYO CO., LTD. | 2003-02-27 | — | — | US | disclosed |
| US-5955241-A | Chemical-amplification-type negative resist composition and method for forming negative resist pattern | TOKYO OHKA KOGYO CO., LTD. (JP) | 1999-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000450-B2 | N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors | SLC6A2, TPH1, SLC6A3 | CTSB 2824/4885CA12 4094/4885CA9 4016/4885 |
| US-20180258038-A1 | N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS | SLC6A2, TPH1, SLC6A3 | CTSB 2824/4885CA12 4094/4885CA9 4016/4885 |
| US-20170166524-A1 | N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS | SLC6A2, TPH1, SLC6A3 | CTSB 2824/4885CA12 4094/4885CA9 4016/4885 |
| US-20140288065-A1 | N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS | SLC6A2, TPH1, SLC6A3 | CTSB 2824/4885CA12 4094/4885CA9 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.